Till is a serial founder and angel investor with over 20 years life science experience in biopharma, diagnostics, digital health, and medtech. He founded Myelo Therapeutics (sold to Eckert & Ziegler AG), Treamid Therapeutics (secondary exit), and IDrug. Till has raised over €40m in venture capital and non-dilutive funding. An engineer and MBA by training, he previously worked in management consulting and in strategy, marketing, and commercial roles at Bayer Pharma and Thermo Fisher Scientific